Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer by Brennan, Donal J et al.
RESEARCH ARTICLE Open Access
Tumour-specific HMG-CoAR is an independent
predictor of recurrence free survival in epithelial
ovarian cancer
Donal J Brennan
1,2*, Jenny Brändstedt
3, Elton Rexhepaj
2, Michael Foley
4, Fredrik Pontén
5, Mathias Uhlén
6,
William M Gallagher
2, Darran P O’Connor
2, Colm O’Herlihy
4, Karin Jirstrom
3,7
Abstract
Background: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the
mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more
favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of
HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer.
Methods: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA)
consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring
model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence
free survival (RFS).
Results: Seventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65%
(n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease
stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged
RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent
predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors
such as residual disease, tumour stage and grade.
Conclusion: HMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As
HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are
required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in
conjunction with current chemotherapeutic regimens.
Background
Epithelial ovarian cancer (EOC) is the leading cause of
death from gyneacological malignancy and the fifth
most common cause of cancer-related death in women.
In 2008 it was estimated that 21,650 new ovarian cancer
cases will be diagnosed in the United States and that
15,520 will succumb to the disease [1]. Despite improve-
ments in surgical techniques and the advent of more
targeted therapeutics such as bevacizumab, survival of
patients with EOC stands at 45% at five years [1]. Such
poor statistics indicate an urgent requirement to
improve our understanding of the molecular mechan-
isms underlying EOC, which may lead to the develop-
ment of improved prognostic and predictive assays.
3-hydroxy-3methylglutharyl-coenzyme A reductase
(HMG-CoAR) acts as a rate-limiting enzyme in the
mevalonate pathway. Although cholesterol represents
the main product of this pathway, it also produces a
number of non-sterol isoprenoid side products, which
have been shown to have a number of tumour-suppres-
sive properties [2] and to be important regulators of
angiogenesis, proliferation, and migration [3,4]. HMG-
CoAR inhibitors (statins), have demonstrable anti-neo-
plastic effects in vitro [5-7] and in xenograft models [7].
Both the isoprenoid-mediated anti-tumoural properties,
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suggested to lower the cancer incidence among statin
users [8], although, to date, epidemiological studies have
been unable to confirm an association between statin
therapy and ovarian cancer risk [9-11].
Members of our group have previously investigated
tumour-specific expression of HMG-CoAR by immuno-
histochemistry (IHC) in 511 incident breast cancer cases
within the population-based prospective cohort Malmö
Diet and Cancer Study [12]. This study demonstrated
that HMG-CoAR was expressed at various intensities in
82% of the tumours and increased levels of HMG-CoAR
protein expression were associated with favourable char-
acteristics, such as a smaller tumour size, low histologi-
cal grade and estrogen receptor (ER) positivity [13]. A
validation study confirmed these findings and demon-
strated that HMG-CoAR was an independent prognostic
marker, associated with an improved recurrence free
survival (RFS) [14].
Based on these data, the prognostic power of tumour-
specifc HMG-CoAR expression in EOC was examined.
This study describes the use of tissue microarray (TMA)
technology to investigate the prognostic value of HMG-
CoAR in EOC and the use of automated image analysis
to quantify HMG-CoAR expression.
Methods
Patients and tumour samples
Prior to commencing the study a power calculation
revealed that a cohort of 54 patients would allow for a
power of 0.95 (G*Power, http://www.psycho.uni-duessel-
dorf.de/aap/projects/gpower/). The TMA, used in this
study was constructed from a consecutive cohort of 76
patients diagnosed with primary invasive epithelial ovar-
ian cancer at the National Maternity Hospital, Dublin,
with a median follow-up of 4.3 years. The patient cohort
has been described previously [15]. The standard surgi-
cal management was a total abdominal hysterectomy,
bilateral salpingo-oophorectomy and omentectomy with
cytological evaluation of peritoneal fluid or washings.
Residual disease was resected to less than 2 cm where
possible. Stage and volume of residual disease (no resi-
dual disease, residual disease greater or less than 2 cm)
were recorded in all cases. All patients received adjuvant
chemotherapy consisting of cisplatin or carboplatin
prior to 1992 and combined with paclitaxel from 1992
to 2002. No patient received neo-adjuvant chemother-
apy. Benign or borderline ovarian cancers, non-epithelial
ovarian cancer and cases with histological features typi-
cal of secondary ovarian cancer were excluded from the
study. Diagnostic specimens were all formalin fixed and
paraffin embedded in the Department of Pathology at
the National Maternity Hospital, Dublin, Ireland. All tis-
sue blocks were stored in that department prior to
construction of the TMA. Full ethical approval was
obtained from the Ethics Committee of the National
Maternity Hospital, Dublin and informed consent was
obtained from living patients and relatives of deceased
patients.
Tissue microarrays and immunohistochemistry
Seventy six paraffin-embedded tumour specimens were
used for tissue microarray (TMA) construction as pre-
viously described [15]. Areas representative of invasive
cancer were marked on haematoxylin and eosin-stained
slides and the TMA was constructed, using a manual
tissue arrayer (MTA-1, Beecher Inc, WI). The array con-
sisted of four cores per patient. Two 1.0 mm cores were
extracted from each donor block and assembled in a
recipient block. Recipient blocks were limited to
approximately 100 cores each. In general, cores were
taken from the peripheral part of the tumour in cases
where the tumour had well-defined borders. In more
diffusely growing tumours, areas with the highest
tumour cell density were primarily targeted. Necrotic
tissue was avoided.
Four μm sections were automatically pretreated using
the PT-link system (DAKO, Copenhagen, Denmark)
before being stained in a Techmate 500 (DAKO, Copen-
hagen, Denmark) with a polyclonal anti-HMG-CoAR
antibody (Upstate, Lake Placid, NY) diluted 1:250 as
described previously [14]. Cytoplasmic staining of
HMG-CoAR was assessed according to intensity (nega-
tive - 0, weak - 1, moderate - 2, strong - 3). When pre-
sent, HMG-CoAR was generally expressed in the
majority of tumour cells (> 50%) and therefore, only the
staining intensity was accounted for in the manual
analyses.
Image Acquisition, Management and Automated analysis
The Aperio ScanScope XT Slide Scanner (Aperio Tech-
n o l o g i e s ,V i s t a ,C A )s y s t e mw a su s e dt oc a p t u r ew h o l e
slide digital images with a 20× objective. Slides were de-
arrayed to visualize individual cores, using Spectrum
(Aperio). Genie™ histology pattern recognition software
(Aperio) was used to identify tumour from stroma in
individual cores and a colour deconvolution algorithm
(Aperio) was used to quantify tumour-specific HMG-
CoAR expression. Estrogen receptor and Ki-67 were ana-
lyzed using a previously described algorithm [16] and a
10% threshold was used for dichomotization of data.
Statistical analysis
Spearman’s Rho correlation was used estimate the rela-
tionship between cores from individual tumours, Pear-
son correlation was used to estimate the relationship
between manual and automated analysis. Differences in
distribution of clinical data and tumour characteristics
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expression (described below) were evaluated using the
c
2 test. Kaplan-Meier analysis and the log rank test
were used to illustrate differences between RFS and
overall survival (OS). Cox regression proportional
hazards models were used to estimate the relationship
between survival and HMG-CoAR, residual disease,
stage and grade. All calculations were performed, using
SPSS version 11.0 (SPSS Inc, Chicago, IL). P values
< 0.05 were considered statistically significant.
Results
Immunohistochemical Expression of HMG-CoAR in
Epithelial Ovarian Cancer
HMG-CoAR expression was evaluable in 72 of 76 cases
(95%). The remaining cores were lost during antibody
optimisation and staining. HMG-CoAR was generally
confined to tumour epithelium and was expressed in
various intensities in the cy t o p l a s m( F i g .1 A ) .S t r o m a l
expression of HMG-CoAR was not seen. Only staining
intensity was accounted for in statistical analysis of
HMG-CoAR protein expression, as when present,
HMG-CoAR was generally expressed in the majority of
tumour cells (> 50%), a finding consistent with previous
studies[13,14]. Nuclear expression of HMG-CoAR was
not detected; however, membranous expression of
HMG-CoAR was evident in a small number of cases
(Fig. 1B). Granular cytoplasmic staining was also seen in
a small number of cases (Fig. 1C) Twenty-five of the 72
tumours (35%) lacked HMG-CoAR expression, 35 (47%)
demonstrated weak, 12 (18%), moderate and none
demonstrated a strong signal. HMG-CoAR expression
was also examined in a panel of normal ovarian and fal-
lopian tube specimens. HMG-CoAR expression was
seen in the majority of normal ovarian and fallopian
tube epithelium (Fig. 1D and 1E).
Figure 1 HMG-CoAR Expression in EOC. Examples of immunohistochemical HMG-CoAR staining in EOC with negative, intermediate and
strong cytoplasmic expression (5× and 20× magnification) (A). Areas of membranous expression (B) and granular staining (C) were also seen
(20× magnification). HMG-CoAR expression was also evident in normal fallopian tube (D) and normal ovarian surface epithelium (E) (20×
magnification).
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Having demonstrated that HMG-CoAR was differen-
tially expressed in EOC, the relationship between HMG-
CoAR expression and prognosis was evaluated. As
tumours were arrayed in quadruplicate, median expres-
sion values were used for survival analysis. Kaplan Meier
analysis demonstrated that HMG-CoAR was associated
with a non-significant stepwise improvement in both
RFS (Fig. 2A) and OS (Fig. 2B). Patients with moderate
(2+) HMG-CoAR expression had a median RFS of 42
months compared to 14 months for patients with
HMG-CoAR-negative tumours.
Based on these findings a dichotomized variable com-
paring absent versus any staining was defined. This
revealed that HMG-CoAR expression was associated
with a prolonged RFS (p = 0.016) and a trend towards a
prolonged OS (p = 0.061). Cox univariate analysis (Table
1) confirmed that HMG-CoAR expression was associated
with an improved RFS (HR = 0.52, 95% CI 0.30 - 0.91,
p = 0.022) and multivariate regression analysis of RFS
revealed that after adjusting for stage and grade, HMG-
CoAR was still a significant predictor of improved RFS
(HR = 0.54, 95% CI 0.30 - 0.96, p = 0.036) (Table 1).
Automated Analysis Confirms HMG-CoAR as a Good
Prognostic Marker
Our group has previously demonstrated that automated
analysis of IHC can identify new prognostic subgroups
[15-17], and automated analysis was used in this study
to develop a quantitative scoring model for HMG-CoAR
expression in EOC. The approach adopted in this study
differed from previous experiments as pattern recogni-
tion software (Genie, Aperio) was initially used to iden-
tify tumour from stroma and then tumour-specific
HMG-CoAR expression was quantified using a postive
pixel count algorithm. The output of the algorithm was
staining intensity and percentage positive tumour cells.
The approach is illustrated in Fig. 3.
Figure 2 HMG-CoAR is Associated with Prolonged RFS in EOC. Kaplan Meier analysis of manually assessed HMG-CoAR cytoplasmic intensity
revealed a trend towards an improved RFS (A) and OS (B). Dichotomization of data as positive versus negative revealed that HMG-CoAR was
associated with an improved RFS (C) but not an improved OS (D).
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automated analysis of staining intensity (r = 0.61, p <
0.001) (Fig. 4A). Automated intensity values of duplicate
cores from individual tumour blocks showed an excel-
lent correlation (Spearman’s Rho 0.763, p < 0.001) sug-
gesting a homogenous pattern of expression of HMG-
CoAR in EOC and thus making it suitable for TMA-
based analysis.
Using automated analysis an HMG-CoAR autoscore
combining intensity and percentage positive tumour
cells was developed. As specimens were arrayed in
quadruplicate a median HMG-CoAR autoscore was cal-
culated for each tumour. The distribution of the HMG-
CoAR autoscore is illustrated in Fig. 4B. Cox univariate
analysis of the HMG-CoAR autoscore as a continuous
value revealed that it was associated with an improved
RFS (HR = 0.98, 95% CI 0.97 - 0.99, p = 0.039) (Table
1). No relationship was seen between HMG-CoAR auto-
score and OS (HR = 0.99, 95% CI 0.98 - 1.01, p = 0.41).
Cox multivariate analysis of HMG-CoAR autoscore as a
continuous variable confirmed increased expression of
HMG-CoAR protein was associated with an improved
RFS after controlling for stage and grade (HR = 0.98,
95% CI 0.97 - 0.99, p = 0.040) (Table 1).
HMG-CoAR autosore was then dichotomised using the
25
th percentile (corresponding to an autoscore value of
35) as a threshold. Kaplan Meier analysis of the HMG-
CoAR as a dichotomised value demonstrated that
increased levels of HMG-CoAR protein expression were
associated with an improved RFS (p = 0.012) (Fig. 4C). A
high HMG-CoAR autoscore was associated with a non-
significant trend towards an improved OS (p = 0.131)
(Fig. 4D). Cox univariate analysis of dichotomised HMG-
CoAR autoscore confirmed the association between
H M G - C o A Rp r o t e i ne x p r e s s i o na n dap r o l o n g e dR F S
(HR = 0.47, 95% CI 0.25 - 0.87, p = 0.017). Cox multivari-
ate analysis controlling for grade, stage and residual dis-
ease revealed that increased levels of HMG-CoAR
protein expression, as demonstrated by a high HMG-
CoAR autoscore, was an independent predictor of a RFS
in EC (HR = 0.49, 95% CI 0.25 - 0.993, p = 0.03) (Table
1). No relationship was evident between HMG-CoAR
expression and age, grade, stage, histological subtype,
estrogen receptor or Ki-67 status (Table 2).
Discussion
This is, to our knowledge, the first study to describe
tumour-specific HMG-CoAR expression in EOC. Cyto-
plasmic expression of HMG-CoAR was evident in vary-
ing intensities in 65% of the tumours. Although HMG-
CoAR was not associated with disease stage, grade,
estrogen receptor or Ki-67 expression, it was associated
with a prolonged RFS. Manual and automated quantifi-
cation of HMG-CoAR expression were both associated
with a prolonged RFS and Cox multivariate proportional
hazards analysis confirmed that this was independent of
stage and grade. These findings support previous results
from our group describing the association between
tumour-specific HMG-CoAR expression in breast cancer
and a less aggressive tumour phenotype [13,14].
As HMG-CoAR is the rate-limiting enzyme of the
mevalonate pathway, these data add further evidence of
this pathway’s importance in tumour development and
progression. While HMG-CoAR inhibitors, also known
Table 1 Cox regression analysis of RFS based on manual and automated assessment of HMG-CoAR expression.
Manual Analysis Autoscore Continuous Autoscore Dichotomised
HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value
Univariate Univariate Univariate
HMG-CoAR
(high versus low)
0.52 (0.30-0.91) 0.022 0.98 (0.97 – 0.99) 0.039 0.47 (0.25 – 0.87) 0.017
Stage
(continuous)
2.17 (1.16-4.03) 0.015 2.17 (1.16 - 4.03) 0.015 2.17 (1.16 - 4.03) 0.015
Grade
(Low versus moderate and high)
1.32 (0.62-2.81) 0.471 1.32 (0.62 - 2.81) 0.471 1.32 (0.62 - 2.81) 0.471
Resdiual Disease
(no macrscopic disease v’s macroscopic disease)
0.79 (0.35-1.81) 0.58 0.79 (0.35 - 1.81) 0.58 0.79 (0.35 - 1.81) 0.58
Multivariate* Multivariate* Multivariate*
HMG-CoAR
(high versus low)
0.52 (0.30-0.96) 0.036 0.99 (0.97 – 0.99) 0.04 0.49 (0.25 – 0.99) 0.03
Stage
(continuous)
1.31 (0.61-2.80) 0.485 1.33 (0.64-2.77) 0.447 1.40 (0.66 - 2.95) 0.373
Grade
(Low versus moderate and high)
2.03 (0.66-6.27) 0.216 1.15 (0.43-3.07) 0.777 1.28 (0.49 - 3.29) 0.61
Resdiual Disease
(no macrscopic disease v’s macroscopic disease)
0.40 (0.12 1.29) 0.123 0.87 (0.53 - 1.45) 0.597 0.88 (0.53 - 1.50) 0.621
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treatment of hypercholesterolemia and cardiovascular
disease, their role in oncology remains relatively unpro-
ven. Despite an ever-growing body of literature describ-
ing the anti-neoplastic properties of statins,
epidemiologic data regarding their preventive effect
against cancer in general, and EOC in particular, remain
inconclusive [9,10,18-22]. A recent pre-operative win-
dow trial of ductal carcinoma in situ and stage one
breast cancer was the first to demonstrate that statins
can inhibit proliferation and increase apoptosis in vivo
[23]. This raises the possibility that the combination of
statins and well-established chemotherapeutic agents
m a yb ea no p t i o ni nt h en e o - a d j u v a n ts e t t i n gi no t h e r
tumour types also.
HMG-CoAR activity in tumou rc e l l si se l e v a t e da n d
dysregulated. HMG-CoAR activity in leukemia cells
[24,25] and lung carcinoma cells [26] are 3-8-fold and
2-fold higher, respectively, than in normal cells. Further-
more, statin induced mevalonate depletion has been
shown to result in an adaptive induction of HMG-CoAR
expression in chinese hamster ovary cells [27] and
MCF-7 breast cancer cells [28]. Treatment of MCF-7
cells with mevastatin resulted in a 10- to 15-fold induc-
tion of HMG-CoAR activity in association with a 2.5- to
3.5-fold induction of HMG-CoA reductase mRNA
Figure 3 Automated Analysis of HMG-CoAR Protein Expression. Using Genie pattern recognitiion software, tumour and stroma were
identified and tumour specific HMG-CoAR was quantified using a colour deconvolution algorithm. The images shown are IHC and mark-up
images, markups show different levels of HMG-CoAR as described by the colour coded legend.
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may increase tumour specific HMG-CoAR expression in
vivo, however this remains to be fully elucidated. It
seems counterintuitive that statins cause an increase in
tumour-specifc HMG-CoAR expression however this is
felt to be secondary to a loss of sterol mediated inhibi-
tion of HMG-CoAR transcription in tumour cells [2].
The statin induced increase in HMG-CoAR results in
an increase non-sterol isoprenoid side products, with
their associated tumour-suppressive properties, which
may explain the efficacy of statin in treating tumour
cells in vitro [2]
Kato et al recently demonstrated that lypophillic sta-
tins induce apoptosis in ovarian cancer cells, and also
postulated that HMG-CoAR expression predicted
response to statin treatment [29]. In vitro data demon-
strate that statins induce apoptosis and inhibit tumour
formation in soft agar in ovarian cancer cells via activa-
tion of the JNK pathway and pro-apoptotic proteins
such as Bim [30]. Additionally statin induced suppres-
sion of RhoA has been shown to inhibit peritoneal dis-
semination of ovarian cancer cells in vivo [31]. Likewise
high-dose lovastatin has been shown to inhibit tumour
proliferation in a xenograft model of anaplastic thyroid
cancer [32].
It has been postulated that the anti-neoplastic effects
of statins could be attributed to their ability to increase
HMG-CoAR activity in tumour cells, thus leading to the
production of non-sterol bi-products of the mevalonate
pathway [2]. Increased HMG-CoAR activity increases
the synthesis of farnesyl diphosphate and geranylgeranyl
diphosphate. These substrates provide the isoprenoid
moieties for the post-translational modification of the
cysteine residue of the conserved carboxyl terminus
Figure 4 HMG-CoAR Autoscore is Associated with an Improved RFS. There was an excellent correlation between automated and manual
cytoplasmic intensity (A). A HMG-CoAR autoscore was calculated by combining cytoplasmic intensity and the percentage of positive tumour
cells. The distribution of the HMG-CoAR autoscore is illustrated in the histogram (B). Using a threshold of the 25th percentile, an increased HMG-
CoAR autoscore was associated with a prolonged RFS (C) but not OS (D).
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Prenylation has been shown to have a number of
tumour suppressive actions including the induction of
apoptosis [33], the initiation of G1 arrest [33] and the
suppression of small G-protein receptors and intracellu-
lar growth pathways [34]. HMG-CoAR expression could
be a surrogate marker of protein prenylation, thus
explaining our findings that increased levels of HMG-
CoaR are associated with an improved prognosis in both
breast and EOC.
Conclusion
In summary, this is the first description of tumour-spe-
cific HMG-CoAR expression in EOC. Given that all of
the patients in this study received adjuvant platinum-
based chemotherapy, these data suggest that the addi-
tion of statins to traditional chemotherapeutic regimens
may be an efficacious and well-tolerated strategy in
EOC. Although data were not available on statin use in
this cohort, a growing body of experimental evidence
exists describing a synergism between cisplatinum and
statins in vitro [35-37]. Recent in vivo data confirmed
that statins have an anti-neoplastic effect in breast
cancer [23] and it is anticipated that ongoing prospec-
tive trials will shed more light on this issue [38]. It
should also be noted that while further studies are
required to investigate the value of HMG-CoAR expres-
sion as a predictive marker of response to statin treat-
ment, our results provide evidence to justify prospective
randomized controlled trials examining the addition of
statins to standard adjuvant chemotherapeutic regimens
for EOC.
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